Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.

Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ

doi:10.1021/ic061008y

Back

Journal article

Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.

Ang WH Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.
Daldini E
Scolaro C
Scopelliti R
Juillerat-Jeannerat L
Dyson PJ

2006-10-24

Published in:

Inorganic chemistry. - 2006

Drug Screening Assays, Antitumor

English With a view to develop drugs that could resist hydrolysis in aqueous media, organometallic arene-capped ruthenium(II) 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (RAPTA) complexes bearing chelating carboxylate ligands have been prepared and studied. The new complexes, Ru(eta6-cymene)(PTA)(C2O4) (1) and Ru(eta6-cymene)(PTA)(C6H6O4) (2), were found to be highly soluble and kinetically more stable than their RAPTA precursor that contains two chloride ligands in place of the carboxylate ligands. They were also able to resist hydrolysis in water and exhibited significantly lower pKa values. Importantly, they showed a similar order of activity in inhibiting cancer cell-growth proliferation (as determined by in vitro assays) and exhibited oligonucleotide binding characteristics (as evidenced by matrix-assisted laser desorption ionization mass spectrometry) similar to those of the RAPTA precursor, hence realizing a strategy for developing a new generation of stable and highly water-soluble RAPTA adducts.

Language